International Psoriasis Council
Advancing Knowledge. Improving Care.
A new regional collaboration led by IPC and partner organizations aims to improve diagnosis, treatment, and care coordination for psoriasis
The International Psoriasis Council (IPC) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) have launched
Learn how psoriasis connects to psoriatic arthritis, cardiovascular disease, obesity, and mental health in IPC’s World Psoriasis Day 2025 campaign.
The International Psoriasis Council (IPC) joined IFPA and regional leaders at the IFPA Forum Americas in Bogotá to promote access,
Discover the new free psoriasis course on WHOAcademy, created by IPC and IFPA for the WHO. Enhance your knowledge of
IPC welcomes Takeda Pharmaceuticals as a 2024 Bronze Level Corporate Member. See how Takeda’s innovative research and commitment to patient
Join us in honoring the life and legacy of Dr. Hoseah Waweru, esteemed President of IFPA, whose dedication and compassion
Highlighting a decade of psoriasis advocacy. IPC is pleased to join IFPA in celebrating the 20th anniversary of the World
In 2022, IFPA and IPC announced a new partnership to join their clinical expertise and the patient perspective. Here’s what
The International Psoriasis Council (IPC) and Scientific Education Support (SES) are excited to announce a strategic collaboration aimed to improve
The IPC is a proud supporter of World Psoriasis Day by uniting for action with IFPA to advance care and
The Global Psoriasis Atlas (GPA) is a joint project of the ILDS (International League of Dermatological Societies), IFPA (International Federation
Annually, the IPC Board selects a specific subject of importance and commissions a group of experts to conduct a best
PsoProtect, a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data
IPC is pleased to welcome AnaptysBio as a Bronze Level Corporate Member!
Biologics and biosimilars have created many new options in psoriasis treatment for patients worldwide, but patients worldwide face barriers to
According to a new paper published by the team behind the PsoProtect registry, psoriasis patients treated with biologics are at
The registries, PsoProtect and PsoProtectMe, aim to help health care workers understand how the novel virus affects patients with psoriasis.
In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.
What were the key takeaways from the 2026 AAD Annual Meeting? IPC shares updates on diagnostic challenges, psoriasis therapies, and late-breaking research from leading experts.
A new regional collaboration led by IPC and partner organizations aims to improve diagnosis, treatment, and care coordination for psoriasis and psoriatic arthritis across Latin America.
IPC recognizes its 2025 Fellows as IPC Jr. Councilors following the completion of their fellowship. This transition recognizes their contributions to psoriasis research, education, and global collaboration, and marks their expanded role in the IPC network.
The International Psoriasis Council welcomes Mari Løset and Maxwell Sauder as new Councilors, supporting IPC’s global mission in psoriasis research and care.
In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.